We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current NEU market cap is 1.59B. The company's latest EPS is NZD 1.2301 and P/E is 10.13.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| NZD ($) | NZD ($) | NZD ($) | NZD ($) | NZD ($) | |
| Total Revenue | 495k | 817k | 3.2M | 15.42M | 231.94M |
| Operating Income | -11.34M | -8.71M | -8.23M | -1.43M | 197.02M |
| Net Income | -10.82M | -9.19M | -7.79M | 184k | 157.08M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| NZD ($) | NZD ($) | NZD ($) | NZD ($) | NZD ($) | |
| Total Assets | 14.41M | 24.95M | 40.06M | 43.27M | 247.97M |
| Total Liabilities | 559k | 753k | 803k | 1.68M | 42.76M |
| Total Equity | 13.85M | 24.2M | 39.25M | 41.59M | 205.21M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| NZD ($) | NZD ($) | NZD ($) | NZD ($) | NZD ($) | |
| Operating | -11.72M | -8.08M | -9.97M | 3.6M | 184.93M |
| Investing | -12k | -6k | -10k | -19k | -211.49M |
| Financing | 1.86M | 19.14M | 22.18M | -2k | 3.62M |
| Market Cap | 1.59B |
| Price to Earnings Ratio | 10.13 |
| Price to Sales Ratio | 6.86 |
| Price to Cash Ratio | 93.05 |
| Price to Book Ratio | 7.75 |
| Dividend Yield | - |
| Shares Outstanding | 127.7M |
| Average Volume (1 week) | 705.46k |
| Average Volume (1 Month) | 586.74k |
| 52 Week Change | -19.61% |
| 52 Week High | 170.09 |
| 52 Week Low | 12.02 |
| Spread (Intraday) | 0.21 (1.66%) |
| Company Name | Neuren Pharmaceuticals Limited |
| Address |
suite 201 auckland |
| Website | https://www.neurenpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
